Last reviewed · How we verify

pirfenidone and nintedanib

Hospices Civils de Lyon · FDA-approved active Small molecule Quality 5/100

pirfenidone and nintedanib is a Small molecule drug developed by Hospices Civils de Lyon. It is currently FDA-approved.

At a glance

Generic namepirfenidone and nintedanib
SponsorHospices Civils de Lyon
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about pirfenidone and nintedanib

What is pirfenidone and nintedanib?

pirfenidone and nintedanib is a Small molecule drug developed by Hospices Civils de Lyon.

Who makes pirfenidone and nintedanib?

pirfenidone and nintedanib is developed and marketed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What development phase is pirfenidone and nintedanib in?

pirfenidone and nintedanib is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing